{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-311070","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.346679+00:00","generated_at":"2026-06-20T23:56:59.414360+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst Pharma to acquire U.S. rights of FYCOMPA from Eisai for $160M upfront","bullets":["$160M upfront at closing; potential $25M milestone if patent exclusivity extended to June 2026.","FYCOMPA U.S. net revenues approx. $136M for Eisai fiscal year ending March 2023.","Deal expected to be EBITDA and EPS accretive in 2023; all-cash, no financing contingencies.","Includes exclusive option to evaluate and negotiate acquisition of a rare epilepsy pipeline asset.","Expected close Q1 2023, subject to customary closing conditions and U.S. regulatory clearances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-311070","json":"https://secwatch.observer/filing/0001193125-22-311070.json","markdown":"https://secwatch.observer/filing/0001193125-22-311070.md","text":"https://secwatch.observer/filing/0001193125-22-311070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/0001193125-22-311070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/d432372d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:56:59.414360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55be404472ee95bae0b14bb87e9c92f6a3c7f518","claim":"CATALYST PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Eisai Co., Ltd valued at $160 million (effective 2022-12-17).","evidence_excerpt":"On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Eisai Co., Ltd (“ Eisai ”), pursuant to which the Company has agreed to acquire from Eisai the U.S. rights for FYCOMPA ® (perampanel) CIII.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/0001193125-22-311070-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Eisai Co., Ltd"},{"label":"Value","value":"$160 million"},{"label":"Effective","value":"2022-12-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}